Jerini Overview

  • Founded
  • 1984

Founded
  • Status
  • Acquired/​Merged

  • Employees
  • 65

Employees
  • Latest Deal Type
  • M&A

  • Financing Rounds
  • 4

Jerini General Information

Description

Developer and marketer of peptide-based drugs. The company offers Firazyr (Icatibant) for the treatment of acute attacks of hereditary angioedema. Its developing product pipeline includes JSM 6427, a a5ß1 Integrin antagonist for the treatment of cancer, age-related mascular degeneration-blindness in the elderly, and angiogenesis, inflammation, and fibrosis; and JSM-7717 and JPE-1375, which are C5a receptor antagonists for the treatment of inflammatory and ophthalmological diseases.

Contact Information

Website
www.jerini.de
Ownership Status
Acquired/Merged
Financing Status
Formerly PE-Backed
Primary Industry
Drug Discovery
Other Industries
Pharmaceuticals
Acquirer
Primary Office
  • Invalidenstrasse 130
  • 10115 Berlin
  • Germany

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Jerini Valuation & Funding

Deal Type Date Amount Valuation/
EBITDA
Post-Val Status Debt

This information is available in the PitchBook Platform. To explore Jerini‘s full profile, request access.

Request a free trial

Jerini Patents

Jerini Recent Patent Activity

Publication ID Patent Title Status First Filing Date Technology (CPC) Citations
CA-2752190-A1 Small molecule bradykinin b1 receptor antagonists Abandoned 13-Feb-2009 0000000000
EP-2396301-A2 Small molecule bradykinin b1 receptor antagonists Withdrawn 13-Feb-2009 0000000000
EP-2344477-A1 Small molecule bradykinin b2 receptor modulators Withdrawn 22-Sep-2008 0000000000
EP-2344176-A1 Use of bradykinin b1 receptor antagonists in intestinal fibrosis treatment Withdrawn 18-Sep-2008 0000000000
JP-2009536961-A Novel heterocyclic compounds inhibiting integrins and uses thereof Pending 12-May-2006 C07D405/12
To view Jerini’s complete patent history, request access »

Jerini Signals

Growth Rate

0.80% Weekly
Growth
Weekly Growth 0.80%, 93rd %
-35.5%. 530%

Size Multiple

219x Median
Size Multiple 219x, 100th %ile
0.00x 0.95x. 413Kx

Key Data Points

Twitter Followers

5.5k

Similarweb Unique Visitors

15.0K

Majestic Referring Domains

314

PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.

Request a free trial

Jerini Former Investors

Investor Name Investor Type Holding Investor Since Participating Rounds Contact Info

This information is available in the PitchBook Platform. To explore Jerini‘s full profile, request access.

Request a free trial